Cannabinoid derived pharmaceuticals have faced many challenges in their development. Cannabis prohibition being the original and biggest obstruction to progress. Now the industry has started facing new, more acute challenges like finding suitable patient populations and designing robust trials, working with regulators around the world with varying attitudes towards cannabis, selecting the most pharmacologically appropriate synthetic or phytocannabinoid possible just to name a few. Along with the challenges COVID-19 has created over the past months many of these other challenges have been facing the industry for years.
Introducing the first Cannabinoid Derived Pharmaceuticals Industry Review Summit, taking place virtually 19th – 21st January. Attending online will give you access to the same opportunities as a physical attendee through our purpose-built online conference platform.
With 20+ hours of content, an interactive pre-conference funding and finance workshop and 5 hours+ of networking with your fellow drug developers, this is the only conference solely focused on the application of cannabinoids for pharmaceutical use in a range of disease indications.
Join us as we unite experts from across large pharma, innovative biotechs, academia and solution providers to overcome all the end to end challenges which are holding back therapeutic and commercial success in cannabinoid-based drug development.
“The inspiration in this meeting is the merging of minds in the field to better understand hurdles that become business opportunities”
Eyal Ballan, Co-founder and CTO, Cannabics Pharmaceuticals
“Cannabinoid medicine has incredible potential that has only recently become the object of rigorous scientific investigation. It is important for those working in the field to share knowledge and ideas to expedite the understanding and development of these new therapies”
Andrea Leone-Bay, CSO and Founder, Receptor Life Sciences
“The present summit is a unique opportunity to exchange ideas and share achievements in our multifaceted area of development new therapeutics based on and derived from phyto-cannabinoids”
Shimon Lecht, Chief R&D Officer, CannRx